1. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship;Mendel;Clin. Cancer Res.,2003
2. Tufts Center for the Study of Drug Development Impact Report (2006) New drugs entering clinical testing in top 10 firms jumped 52% in 2003–05. Analysis and Insight into Critical Drug Development Issues, 8, Tufts University